BRAKKE® Tablets
Composition:
Each film-coated tablet contains:
- Ofloxacin I.P. ...................................................………… 200 mg.
- Ornidazole I.P. ....................................................……. 500 mg.
- Excipients ...........................................................………. q.s.
- Colour: Titanium Dioxide I.P.
Description
- Microbial infections are quite common in lower respiratory tract infections, post-surgical procedures , acute diarrhoea and dysentery.
- Ofloxacin is a fluorinated quinolone with a broad-spectrum coverage against gram-negative bacteria, gram-positive bacteria, and also some anaerobes, whereas, Ornidazole is a 5-nitroimidazole derivative having broad-spectrum antimicrobial activity against protozoa and certain anaerobic bacteria. Combining the two results in a true broad-spectrum activity to treat systemic infections of mixed aerobic/anaerobic/ protozoal etiology, in all situations where time is critical and laboratory investigations are not feasible.
Indications
- BRAKKE® Tablet is indicated for the empirical treatment of mixed aerobic-anaerobic and protozoal infections commonly seen in clinical practice, e.g. intra-abdominal infection, gynaecological and pelvic infections, lung abscess, and acute diarrhoea or dysentery due to mixed infections.